NTLA
Intellia Therapeutics Inc
NASDAQ: NTLA · HEALTHCARE · BIOTECHNOLOGY
$13.48
+8.32% today
Updated 2026-04-30
Market cap
$1.48B
P/E ratio
—
P/S ratio
21.87x
EPS (TTM)
$-3.81
Dividend yield
—
52W range
$7 – $28
Volume
5.1M
Intellia Therapeutics Inc (NTLA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.69M | $82.14M | $298.97M | $376.24M | $347.31M | $334.28M | $676.32M | $1.29B | $1.52B | $1.30B | $1.19B |
| Cash & equivalents | $9.85M | $75.82M | $273.06M | $340.68M | $58.86M | $57.23M | $160.02M | $123.41M | $523.51M | $226.75M | $189.18M |
| Current assets | $10.13M | $77.63M | $281.31M | $354.83M | $324.98M | $289.48M | $616.52M | $769.30M | $1.22B | $998.33M | $639.86M |
| Total liabilities | $3.13M | $14.78M | $89.13M | $75.64M | $69.39M | $64.40M | $149.25M | $254.22M | $284.53M | $250.81M | $319.06M |
| Current liabilities | $2.35M | $10.70M | $30.73M | $31.36M | $40.57M | $35.63M | $64.25M | $125.83M | $126.55M | $115.21M | $110.85M |
| Long-term debt | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Shareholder equity | $7.57M | $67.36M | $209.84M | $300.60M | $277.92M | $269.88M | $527.07M | $1.04B | $1.24B | $1.05B | $871.96M |
| Retained earnings | $-9.54M | $-21.94M | $-53.57M | $-121.11M | $-201.03M | $-300.88M | $-435.11M | $-703.00M | $-1.18B | $-1.66B | $-2.18B |
| Accounts receivable | — | $1.00M | $6.45M | $10.47M | $7.55M | $4.62M | $2.13M | $2.03M | $3.77M | $36.46M | $8.52M |
| Inventory | — | — | $1.00 | $1.00 | $1.00 | $1.00 | $-19.15M | $-337.36M | $-69.34M | — | — |
| Goodwill | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — |